Search - tctmd.com

Displaying 1 - 20 of 62

Sort: Relevancy | Date

News Daily News

FDA Approves Aficamten for Obstructive HCM

L.A. McKeown

December 29, 2025

News Daily News

Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT

Todd Neale

December 15, 2025

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

Caitlin E. Cox

August 30, 2025

News Conference News ESC 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Michael O'Riordan

August 29, 2025

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Caitlin E. Cox

July 14, 2025

News Conference News ESC Heart Failure 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

Todd Neale

May 19, 2025

News Daily News

Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM

Caitlin E. Cox

March 21, 2025

News Daily News

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Michael O'Riordan

February 12, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

News Daily News

Vascular Disease History Need Not Preclude Aspirin Withdrawal After HeartMate 3

Yael L. Maxwell

January 15, 2025

News Daily News

Top Heart Failure News of 2024

Todd Neale

December 31, 2024

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

L.A. McKeown

November 25, 2024

News Conference News HFSA 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

L.A. McKeown

October 04, 2024

News Conference News ESC 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

L.A. McKeown

August 30, 2024

News Daily News

FDA Approves Dropping Aspirin for HeartMate 3 LVAD Patients

L.A. McKeown

August 21, 2024

News Opinion CV Team Dispatch

July 2024 Dispatch for the CV Team

L.A. McKeown

July 01, 2024

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Caitlin E. Cox

April 15, 2024

News Opinion Off Script

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Sanjay Kaul, MD

March 29, 2024

Advertisement

FDA Approves Aficamten for Obstructive HCM

Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM

Acoramidis Approved in Europe for ATTR Cardiomyopathy

January 2025 Dispatch for the CV Team

Vascular Disease History Need Not Preclude Aspirin Withdrawal After HeartMate 3

Top Heart Failure News of 2024

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

FDA Approves Dropping Aspirin for HeartMate 3 LVAD Patients

July 2024 Dispatch for the CV Team

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content